Description
A novel dual agonist targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously. FDA-approved as Mounjaro (T2DM) and Zepbound (obesity). Produced by Eli Lilly. Demonstrated superior weight loss vs. semaglutide (SURMOUNT-5 head-to-head trial).
Benefits:
Superior weight loss vs. semaglutide (avg 20-22.5% with Zepbound vs ~15% Wegovy); superior glycemic control in T2DM; improved lipid profiles; blood pressure reduction; heart failure outcomes improvement (SUMMIT trial); significant fat mass reduction; preservation of lean mass (relative to weight lost)
Side Effects:
Nausea (common, especially during dose escalation); vomiting; diarrhea; constipation; decreased appetite; gallbladder disease (cholelithiasis); pancreatitis (rare); thyroid C-cell tumor risk (animal studies – class warning); injection site reactions; potential muscle mass loss; hypoglycemia (with insulin)
For laboratory research only — not for human consumption.
Reviews
There are no reviews yet.